Skip to content

2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses

2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05126953
Enrollment
30
Registered
2021-11-19
Start date
2021-09-21
Completion date
2021-09-23
Last updated
2025-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contact Lens Wearer

Brief summary

The objective of this 2 hour study is to evaluate the clinical performance of samfilcon A lenses with an alternate packaging solution (EPG01) compared to commercially available B+L Ultra lenses.

Interventions

DEVICEsamfilcon A Lenses with EPG01 Packaging Solution

samfilcon A Lenses with EPG01 Packaging Solution

DEVICECommercially Available B+L Ultra Lenses

Commercially Available B+L Ultra Lenses

Sponsors

Bausch & Lomb Incorporated
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Be 18 years or older on the date the Informed Consent Form (ICF) is signed and have capacity to read, understand and provide written voluntary informed consent. 2. Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings. 3. Have no active ocular disease or allergic conjunctivitis. 4. Not be using any topical ocular medications. 5. Be willing and able to follow instructions. 6. Have signed a statement of informed consent.

Exclusion criteria

1. Participating in a conflicting study in the opinion of the Investigator. 2. Considered by the Investigator to not be a suitable candidate for participation.

Design outcomes

Primary

MeasureTime frameDescription
Normalized logMAR Visual AcuityAssessed at 2-hour post-baselineNormalized logMAR visual acuity is the change in visual acuity (how well you can see) from baseline (spectacle). Normalized visual acuity is calculated by subtracting the logMAR visual acuity with a contact lens from the baseline (refraction without a contact lens). Each letter on the logMAR visual acuity chart has a value of 0.02.

Countries

United States

Participant flow

Pre-assignment details

This is a contralateral study. 30 subjects were enrolled and were dispensed lenses based on a randomization schedule.

Participants by arm

ArmCount
Samfilcon A Lenses With EPG01 Packaging Solution and Commercially Available B+L Ultra Lenses.
Participants were implanted with both samfilcon A Lenses with EPG01 Packaging Solution and commercially available B+L Ultra lenses.
30
Samfilcon A Lenses With EPG01 Packaging Solution and Commercially Available B+L Ultra Lenses.
Participants were implanted with both samfilcon A Lenses with EPG01 Packaging Solution and commercially available B+L Ultra lenses.
60
Total90

Baseline characteristics

CharacteristicSamfilcon A Lenses With EPG01 Packaging Solution and Commercially Available B+L Ultra Lenses.
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
30 Participants
Age, Continuous40.7 Years
STANDARD_DEVIATION 12.62
Region of Enrollment
United States
30 participants
Sex: Female, Male
Female
12 Participants
Sex: Female, Male
Male
18 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 30
other
Total, other adverse events
0 / 30
serious
Total, serious adverse events
0 / 30

Outcome results

Primary

Normalized logMAR Visual Acuity

Normalized logMAR visual acuity is the change in visual acuity (how well you can see) from baseline (spectacle). Normalized visual acuity is calculated by subtracting the logMAR visual acuity with a contact lens from the baseline (refraction without a contact lens). Each letter on the logMAR visual acuity chart has a value of 0.02.

Time frame: Assessed at 2-hour post-baseline

ArmMeasureGroupValue (MEAN)Dispersion
Samfilcon A Lenses With EPG01 Packaging SolutionNormalized logMAR Visual AcuityINS visit0.005 LogMAR unitsStandard Deviation 0.0577
Samfilcon A Lenses With EPG01 Packaging SolutionNormalized logMAR Visual AcuityFUP visit-0.001 LogMAR unitsStandard Deviation 0.0663
Commercially Available B+L Ultra LensesNormalized logMAR Visual AcuityINS visit0.003 LogMAR unitsStandard Deviation 0.0633
Commercially Available B+L Ultra LensesNormalized logMAR Visual AcuityFUP visit0.008 LogMAR unitsStandard Deviation 0.0632

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026